|
|
Article: Promising Cystic Fibrosis Compound on Track for Development
- Article from:
- U.S. Newswire
- Article date:
- August 15, 2007
CopyrightCopyright 2007 U.S. Newswire. Provided by ProQuest LLC. (Hide copyright information)
|
To: MEDICAL EDITORS
Contact: Laurie Fink, Director of Media Relations of Cystic
Fibrosis Foundation, +1-301-841-2602
BETHESDA, Md., Aug. 15 /PRNewswire-USNewswire/ -- Gilead Sciences,
Inc., one of the world's largest biopharmaceutical companies, and
Parion Sciences, Inc., a development-stage pharmaceutical company,
announced today they will co-develop Parion 680, a compound that
could become an important new drug in treating the basic defect in
cystic fibrosis. This product was identified as part of a $1.7
million award to Parion from Cystic Fibrosis Foundation Therapeutics,
Inc. -- the CF Foundation's nonprofit drug discovery and development